INNL Bleeds Over Dashed Hopes, CRBP To Report Data In Q1, FDA Snubs CEMP


Corbus Pharmaceuticals Holdings Inc. (CRBP) has completed its phase II study of investigational Resunab for the treatment of cystic fibrosis. The topline data from this study are expected in the first quarter of 2017.

A phase II, 12-month open label extension study of Resunab in systemic sclerosis and a phase II study in skin-predominant dermatomyositis, with a 12-month open label extension study in dermatomyositis are ongoing. A phase II study of Resunab in systemic lupus erythematosus is planned to commence in the first quarter of 2017.

CRBP closed Thursday’s trading at $8.60, down 2.82%.

Shares of Cempra Inc. (CEMP) plunged over 57% on Thursday as the FDA refused to approve both oral and intravenous formulations of Solithromycin for the treatment of community-acquired bacterial pneumonia in adults.

Although no further information on Solithromycin efficacy has been requested by the…



Read the full article from the Source…

Join The Discussion